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We recently determined that the nuclear import of cutaneous beta genus HPV8 E7 oncoprotein it is
mediated by its zinc-binding domain via direct hydrophobic interactions with the FG nucleoporins
Nup62 and Nup153 (Onder and Moroianu, 2014). Here we investigated the nuclear export of HPV8 E7
oncoprotein using confocal microscopy after transfections of HeLa cells with EGFP–8cE7 and mutant
plasmids and treatment with Ratjadone A nuclear export inhibitor. We determined that HPV8 E7
contains a leucine-rich nuclear export signal (NES), 76IRTFQELLF84, within its zinc-binding domain that
mediates its nuclear export via a CRM1 pathway. We found that HPV8 E7 interacts with CRM1 and that
the hydrophobic amino acid residues I76, F79 and L82 of the NES are essential for this interaction and for
nuclear export of HPV8 E7 oncoprotein.
& 2014 Elsevier Inc. All rights reserved.
1. Introduction
Nonmelanoma skin cancer (NMSC) is the most common cancer in
fair skinned populations. Exposure to UV radiation, along with fair skin,
immune status and HPV infection, are the greatest risk factors (Akgul
et al., 2006a; Feltkamp et al., 2008). A link between HPV infections and
the development of skin cancer was ﬁrst discovered in patients with
the rare autosomal recessive disorder epidermodysplasia verruciformis
(EV). Among the 14 types of cutaneous HPVs found in skin tumors of
EV patients, the beta genus HPV 5 and 8 are speciﬁcally linked to
malignant lesions and actinic keratoses and have been classiﬁed as
high risk types (Akgul et al., 2006a; Bouwes Bavinck et al., 2008;
Dubina and Goldenberg, 2009; Feltkamp et al., 2008; zur Hausen,
2009). Although EV patients are rare, the incidence of beta genus HPV
associated squamous cell carcinoma (SCC) is highly increased in
immunocompromised patients with beta-HPV DNA being detected in
up to 90% of skin cancers of these individuals (Akgul et al., 2006a).
The HPV E7 proteins are acidic oncoproteins of approximately
98–103 amino acids that contain 3 domains: the conserved region
(CR) 1, CR2, and the carboxyl terminal (C-terminal) domain. The CR1
domain is necessary for cellular transformation and RB degradation in
mucosal high risk HPVs. The CR2 domain contains a conserved pRB
family binding site (LxCxE domain) and a consensus casein kinase II (CKII)
phosphorylation site (McLaughlin-Drubin and Munger, 2009). The C-
terminal domain contains a zinc-binding domain that is composed of
two Cys-X-X-Cys motifs, separated by 29–30 amino acids, and is involved
in dimerization of E7 proteins and associationwith host complexes (Jones
and Munger, 1996; McLaughlin-Drubin and Munger, 2009; Zwerschke
and Jansen-Durr, 2000).
We previously discovered that the E7 oncoproteins of mucosal
high risk HPV16 and low risk HPV11 enter the nucleus via a Ran-
dependent pathway, independent of karyopherins/importins, and
this pathway is mediated by their zinc-binding domain via hydro-
phobic interactions with the FG nucleoporins Nup62 and Nup153
(Angeline et al., 2003; Knapp et al., 2009; McKee et al., 2013; Eberhard
et al., 2013; Piccioli et al., 2010). We also determined that HPV16 E7
and HPV11 E7 contain a leucine-rich NES within their zinc-binding
domain that mediates their nuclear export via a CRM1 pathway
(Knapp et al., 2009; McKee et al., 2013). CRM1 (chromosome region
maintenance 1), a major nuclear export receptor, binds to hydrophobic
leucine-rich NES containing cargoes in a RanGTP dependent manner.
The canonical NES is deﬁned as a L-X2–3-L-X2–3-L-X-L motif, where the
leucine residues can be isoleucine, valine, phenylalanine or methionine
(Hutten and Kehlenbach, 2007). The RanGTP/CRM1/NES cargo com-
plex translocates through the nuclear pore complex and the cargo is
released into the cytoplasm by GTP hydrolysis of RanGTP mediated by
RanGAP (Hutten and Kehlenbach, 2007).
Although the activities, interactions and nucleocytoplasmic trafﬁc of
mucosal alpha genus HPV E7 oncoproteins have been well documen-
ted (McLaughlin-Drubin andMunger, 2009), much less is known about
the cutaneous beta genus HPV E7 proteins. The cutaneous HPV8 E7
oncoprotein has a weaker interaction with pRB than HPV16 E7
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oncoprotein and can transform rodent cells only in collaboration with
an activated H-ras gene (Yamashita et al., 1993). Expression of HPV8 E7
protein in primary human keratinocytes causes polyploidy that is
associated with decreased levels of pRb and p21 (Akgul et al., 2007). It
also causes invasion of human keratinocytes into the dermis of
organotypic skin cultures that is accompanied by overexpression of
extracellular metalloproteinases (Akgul et al., 2005, 2006b).
Flag-HPV8 E7 expressed in transfected human keratinocytes
and EGFP-HPV8 E7 expressed in transfected HeLa cells are both
predominantly localized in the nucleus with some low levels in
the cytoplasm (Sperling et al., 2012; Onder and Moroianu, 2014).
We recently determined that cutaneous beta genus HPV8 E7 onco-
protein contains a cNLS within its zinc-binding domain that mediates
its nuclear import and localization independent of karyopherins/
importins. Furthermore, we discovered that a mostly hydrophobic
patch 65LRLFV69 within the zinc-binding domain mediates nuclear
import and localization of HPV8 E7 via direct hydrophobic interac-
tions with the FG nucleoporins Nup62 and Nup153 (Onder and
Moroianu, 2014).
In this study we investigated the nuclear export of cutaneous HPV8
E7 oncoprotein. We discovered and characterized a leucine-rich NES,
76IRTFQELLF84, within the zinc-binding domain that mediates nuclear
export of HPV8 E7 via a CRM1 pathway. We determined that HPV8 E7
interacts with CRM1 and that the hydrophobic amino acid residues
I76, F79 and L82 of the NES are essential for this interaction and
consequently for nuclear export of HPV8 E7 oncoprotein.
2. Results and discussion
We have previously characterized the leucine-rich NESs located
within the zinc-binding domains of mucosal high risk HPV16 E7
(76IRTLEDLLM84) and low risk HPV11 E7 (76IRQLQDLLL84) mediat-
ing their nuclear export in a CRM1 dependent manner (Knapp et
al., 2009; McKee et al., 2013). The zinc-binding domain of cutaneous
HPV8 E7 oncoprotein also contains a leucine-rich sequence (76IRTF-
QELLF84) that has homology with these previously characterized NESs
of mucosal HPV E7 proteins. To determine if HPV8 E7 oncoprotein can
also undergo nuclear export we used transient transfections in HeLa
cells with plasmids containing enhanced green ﬂuorescent protein
(EGFP) fused to 8cE743–103 and mutants, and Ratjadone A (RJA), a
speciﬁc nuclear export inhibitor that blocks CRM1-mediated nuclear
export of proteins containing leucine-rich NESs. RJA inhibition func-
tions the same way as Leptomycin B (LMB): it covalently modiﬁes a
cysteine residue in the NES-binding pocket of CRM1, thereby inhibiting
NES-binding (Hutten and Kehlenbach, 2007; Meissner et al., 2004). We
analyzed the effect of RJA on the localization of two cysteine mutants,
EGFP–8cE7 CC60AA and EGFP–8cE7 C91A, that we have previously
shown to have a pancellular localization, in contrast with the nuclear
localization of the wild type EGFP–8cE7 (Onder and Moroianu, 2014).
As a positive control for RJA, we used EGFP-16E7–NES, which contains
a fusion of 16E7 with the strong leucine-rich NES of HIV Rev at its C-
terminus (Knapp et al., 2009). Wild type EGFP-16E7 localizes to the
nucleus, and addition of the NES of Rev changes its localization to
cytoplasmic (Knapp et al., 2009). HeLa cells were transfected with
EGFP–8cE7, EGFP–8cE7 CC60AA, EGFP–8cE7 C91A or EGFP-16E7–NES
and examined by confocal microscopy 24 h post transfection. The RJA
treatment was performed after 20 h transfection for 4 h. Quantitative
analysis of ﬁve independent experiments showed a change from
89.972.62% pancellular localization for EGFP–8cE7 CC60AA mutant
in the absence of RJA to 89.671.86% nuclear localization in the
presence of RJA (Fig. 1A, panels E and G; Fig. 1B). Also, the pancellular
localization for EGFP–8cE7 C91A mutant in 88.471.98% cells in the
absence of RJA changed to 88.972.32% nuclear localization in the
presence of RJA (Fig. 1A, panels I and K; Fig. 1B). In the presence of RJA
inhibitor the nuclear export of CC60AA and C91A mutants is inhibited
which allows the accumulation of these mutants (with weakened NLS)
in the nucleus at the steady state analyzed in the transfection assays.
The nuclear localization of EGFP–8cE7 wild type remained largely
unchanged after RJA treatment, with only a small increase in the
percentage of cells with nuclear localization (Fig. 1A, panels A and C;
Fig. 1B). As expected, the cytoplasmic localization of the EGFP-16E7–
NES control changed to nuclear in the majority of transfected cells after
RJA treatment (Fig. 1B). These data suggest the presence of a functional
NES that is masked by a stronger NLS in the C-terminal domain of
cutaneous HPV8 E7 oncoprotein.Similar to HPV16 E7 and HPV11 E7,
HPV8 E7 protein has a leucine-rich NES sequence, 76IRTFQELLF84,
where the bold characters represent the hydrophobic amino acids that
may be critical for the NES function. To characterize this NES sequence
and the amino acids that are essential for its proper function, three NES
mutants were generated in the context of EGFP–8cE7 C91A cysteine
mutant: I76A, F79A and L82A. The C91A mutant was chosen for
generating the three nuclear export mutants because it has only a
minimal mutation that weakens the NLS of HPV8 cE7 and the RJA
export inhibitor rescued its nuclear localization (Figs. 1A and 1B). HeLa
cells were transfected with EGFP–8cE7, EGFP–8cE7 C91A, EGFP–8cE7
C91A/I76A, EGFP–8cE7 C91A/F79A, or EGFP–8cE7 C91A/L82A plasmids
and the intracellular localizations of the expressed EGFP fusion proteins
were analyzed 24 h after transient transfections using confocal ﬂuor-
escence microscopy (Fig. 2). As expected, the majority of cells expres-
sing EGFP–8cE7 showed mostly nuclear localization (Fig. 2, panels
A and C, and Fig. 3), whereas EGFP–8cE7 C91A mutant exhibited
pancellular localization (Fig. 2, panels D and F, and Fig. 3). Interestingly,
the localization of EGFP–8cE7 C91A/I76A, EGFP–8cE7 C91A/F79A, and
EGFP–8cE7 C91A/L82A NES mutants was changed to mostly nuclear
(Fig. 2, panels G and I; J and L; M and O). Quantitative analysis of four
independent experiments showed that all these three NES mutants
exhibited predominant nuclear localization in the majority of cells
similar as the wild type EGFP–8cE7 expressing-cells (Fig. 3). These data
suggest that cutaneous HPV8 E7 has a functional leucine-rich NES
within its C-terminal domain and that the hydrophobic amino acid
residues, I76, F79 and L82 are essential for its nuclear export function.
The identiﬁcation of a functional leucine-rich NES mediating
8E7 nuclear export led us to analyze the interaction between 8E7
and CRM1 nuclear export receptor. HeLa cell lysates containing
EGFP-8E7, EGFP–8cE7, EGFP-16E7–NES (as a positive control), or
EGFP (as a negative control) were incubated with GST-CRM1 or
GST immobilized on glutathione-Sepharose beads. Cell lysates and
the eluted bound proteins were analyzed via immunoblotting with
an anti-GFP antibody. Both EGFP-8E7 and EGFP–8cE7 bound to
GST-CRM1 and not to GST itself (Fig. 4A, lanes 1, 2, 5, 6, 9 and 10),
as well as the positive control EGFP-16E7–NES (Fig. 4A, lanes 3,
7 and 11). EGFP did not interact with either GST-CRM1 or GST
(Fig. 4A, lanes 4, 8 and 12). These data indicate that HPV8 E7
oncoprotein interacts with CRM1 nuclear export receptor via its
zinc-binding domain.
To investigate the role of the leucine-rich NES in the interaction
between 8cE7 and CRM1 we performed isolation assays with all
three NES mutants in comparison with EGFP–8cE7 and EGFP–8cE7
C91A. We found that both EGFP–8cE7 and EGFP–8cE7 C91A bound
to GST-CRM1 but not to GST (Fig. 4B, lanes 1, 2, 7, 8, 13 and 14).
Interestingly, all three NES mutants, EGFP–8cE7 C91A/I76A, EGFP–
8cE7 C91A/F79A and EGFP–8cE7 C91A/L82A did not interact with
GST-CRM1 (Fig. 4B, lanes 3, 4, 5, 9, 10 and 11). As expected, EGFP
did not interact with either GST-CRM1 or GST (Fig. 4B, lanes 6, 12
and 18). These results indicate that these NES mutations inhibit
the interaction of HPV8 E7 with CRM1 supporting the critical role
of the hydrophobic amino acids, I76, F79 and L82 for the nuclear
export function.
Overall, our results indicate that the cutaneous HPV8 E7 oncopro-
tein has a leucine rich NES (76IRTFQELLF84) within the zinc-binding
domain that interacts with CRM1 export receptor and mediates its
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nuclear export. We have previously shown that the mucosal low risk
HPV11 E7 has a leucine-rich NES (76IRQLQDLLL84) within the zinc-
binding domain that interacts with CRM1 (McKee et al., 2013). We also
found that the zinc-binding domain of HPV16 E7 containing the
leucine-rich NES interacts with CRM1 (data not shown). Another
cutaneous beta genus HPV5 E7 protein has also a potential leucine-
rich NES (IRAFQQLL) within its zinc-binding domain that interacts
with CRM1 export receptor (data not shown). This suggests that both
the mucosal and cutaneous HPV E7 oncoproteins have evolved
leucine-rich NESs that would mediate their nuclear export via a
CRM1 pathway.
Overall, this work and a previous study (Onder and Moroianu,
2014) show that cutaneous HPV8 E7 shuttles between the nucleus
and the cytoplasm and localizes predominantly in the nucleus with
low levels in the cytoplasm, reﬂecting the contribution to the HPV8
E7 localization of the NLS and NES, respectively. The mucosal HPV16
E7 and HPV11 E7 oncoproteins also shuttle between the nucleus and
the cytoplasm and this is in agreement with the fact that these HPV
E7 oncoproteins have cellular targets in both cellular compartments.
3. Materials and methods
3.1. Mutagenesis to generate different EGFP-8E7 and EGFP–8cE7
mutants
The EGFP-8E7, EGFP–8cE7, EGFP–8cE7 CC60AA, EGFP–8cE7
C91A plasmids were previously generated (Onder and Moroianu,
Fig. 1. (A) The pancellular localization of two EGFP–8cE7 cysteine mutants changes to nuclear in the presence of RJA, a speciﬁc inhibitor of CRM1 nuclear export receptor.
Twenty hours post-transfection with EGFP–8cE7 (panels A, B, C and D), EGFP–8cE7 CC60AA (panels E, F, G and H) or EGFP–8cE7 C91A (panels I, J, K and L), HeLa cells were
treated with either fresh DMEM (panels A, B, E, F, I and J) or 10 ng/mL RJA (panels C, D, G, H, K and L) for 4 h. After ﬁxation, the cells were examined by confocal microscopy.
Panels A, C, E, G, I and K represent the EGFP ﬂuorescence and panels B, D, F, H, J and L represent the DAPI staining of the nuclei. (B) Quantitative analysis of the intracellular
localization of EGFP–8cE7 and its cysteine mutants in the presence of RJA inhibitor. Twenty hours post-transfection with EGFP–8cE7, EGFP–8cE7 CC60AA, EGFP–8cE7 C91A or
EGFP-16E7NesRev, HeLa cells were treated with either fresh DMEM or 10 ng/mL RJA for 4 h. After confocal microscopy analysis, cells were phenotyped as having either
mostly nuclear (black bars), pancellular (gray bars) or mostly cytoplasmic (striped bars) and the quantitative analysis of ﬁve experiments is represented graphically showing
the average values and standard deviations.
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2014). EGFP–8cE743–103 contains the zinc-binding domain of 8E7
(Onder and Moroianu, 2014). Site-directed mutagenesis was per-
formed to generate EGFP–8cE7 C91A/I76A, EGFP–8cE7 C91A/F79A
and EGFP–8cE7 C91A/L82A using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene) with EGFP–8cE7 C91A as template,
and the corresponding mutagenesis primer pairs. All mutant plasmids
were transformed into XL1-Blue competent cells (Agilent Technolo-
gies), puriﬁed and sequenced for veriﬁcation (Euroﬁns MWG). The
EGFP-16E7NesRev plasmid was previously generated (Knapp et al.,
2009).
3.2. Transient transfections
Transient transfections were performed in HeLa cells (ATCC) as
previously described (Onder and Moroianu, 2014). HeLa cells
plated at 50–70% conﬂuency on 12 mm poly-L-lysine coated glass
coverslips 24 h before transfection were transiently transfected
with the EGFP construct of interest (as indicated in the ﬁgure
legends) using FuGENE 6 Transfection Reagent (Roche Applied
Science, IN). The media was changed to DMEM with 10% FBS and
1% penicillin–streptomycin after 6 h and the cells were ﬁxed with
3.7% formaldehyde in PBS for 10 min. Coverslips were mounted
with Vectashield-DAPI mounting medium (Vector Labs, CA) to
identify the nuclei of cells. Fixed cells were analyzed with a Leica
TCS Sp5 broadband confocal microscope using a 63 immersion
oil objective and 1.6 optical zoom and representative images
were taken using Leica LAS AF software (Leica Microsystems). The
intracellular localization of EGFP-tagged proteins was phenotyped
as either mostly nuclear, pancellular (both in the cytoplasm and
nucleus with no accumulation in either compartments), or mostly
cytoplasmic and data from at least 4 experiments were quanti-
tated and graphical representations were used to display average
values and standard deviations.
3.3. Ratjadone A (RJA) treatment
Twenty hours post-transfection with EGFP fusion plasmids one
set of HeLa cells were treated with 10 ng/mL RJA (Calbiochem) in
Fig. 2. Mutations in the potential NES change the localization of the EGFP–8cE7 C91A mutant from pancellular to nuclear. HeLa cells expressing either EGFP–8cE7 (panels A,
B and C), EGFP–8cE7 C91A (panels D, E and F), EGFP–8cE7 C91A/I76A (panels G, H and I), EGFP–8cE7 C91A/F79A (panels J, K and L) and EGFP–8cE7 C91A/L82A (panels M, N
and O) were ﬁxed 24 h after transfection and examined by confocal microscopy. Panels A, D, G, J and M represent EGFP ﬂuorescence, while panels B, E, H, K and N represent
DAPI staining of the nuclei and panels C, F, I, L and O represent merge images.
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DMEMþ for 4 h in the dark, as previously described (McKee et al.,
2013). After treatment, cells were ﬁxed and analyzed by confocal
microscopy as previously described. EGFP-16E7 tagged with the
nuclear export signal of HIV-Rev (EGFP-16E7NesRev) was used as a
positive control for the RJA experiments.
3.4. Puriﬁcation of GST fusion proteins
The GST-CRM1 plasmid was kindly provided by Dr. Jorgen
Kjems. Escherichia coli BL21 CodonPlus cells (Agilent Technologies)
previously transformed by either GST-CRM1 or GST plasmid were
induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at
37 oC for 2 h. The proteins were then puriﬁed in their native state
on glutathione-Sepharose beads (GE Healthcare) according to a
standard puriﬁcation procedure. The eluted proteins were checked
for purity and lack of degradation by 12% SDS-PAGE and Coomas-
sie Blue staining, and they were stored in aliquots at 80 oC until use.
3.5. In vitro isolation assays
Before performing the isolation assays, GST-CRM1 and GST immo-
bilized on glutathione-Sepharose beads were analyzed by SDS-PAGE
and Coomassie blue staining to ensure the proteins were intact and
bound to beads at similar levels. Equal amounts of cellular lysates (in
volume) containing either EGFP–8cE7, EGFP–8cE7 C91A, EGFP–8cE7
C91A/I76A, EGFP–8cE7 C91A/F79A, EGFP–8cE7 C91A/L82A or EGFP
and 1mM GTP-γS were incubated with either GST-CRM1 or GST
immobilized on glutathione-Sepharose beads for 1 h at 4 1C. Cellular
lysates and the eluted bound proteins were analyzed by immunoblot-
ting with anti-GFP antibody (Clontech).
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